Massachusetts Institute of Technology

The Broad Institute, Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Harvard College

Rutgers, the State University of New Jersey

Aaron Smargon

Feng Zhang

David Arthur Scott

Winston X Yan

Neena Pyzocha

Jonathan S Gootenberg

Patrick D Hsu

David Benjamin Turitz Cox

Eric S Lander

Konstantin Severinov

Eugene Koonin

Kira S Makarova

Yuri I Wolf

Sergey Shmakov

David Cox

Mohammed Reza Mirzazadeh

Nicola Crosetto

Reza Mirzazadeh

Disclosed here is a method of identifying novel CRISPR effectors, comprising: identifying sequences in a genomic or metagenomic database encoding a CRISPR array; identifying one or more Open Reading Frames (ORFs) in said selected sequences within 10 kb of the CRISPR array; discarding all loci encoding proteins which are assigned to known CRISPR-Cas subtypes and, optionally, all loci encoding a protein of less than 700 amino acids; and identifying putative novel CRISPR effectors, and optionally classifying them based on structure analysis.

Methods for identifying class 2 crispr-cas systems

The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA or RNA-targeting systems comprising a novel DNA or RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.

Crispr enzymes and systems

The invention provides for systems, methods, and compositions for targeting RNA. In particular, the invention provides a non-naturally occurring or engineered RNA-targeting system comprising an RNA-targeting Cas protein and at least one RNA-targeting guide RNA, wherein said RNA-targeting guide RNA is capable of hybridizing with a target RNA in a cell.

RNA-targeting system

The invention provides for systems, methods, compositions, and kits for the complete characterization of targeted nuclease specificity which necessitates techniques that can assess the full possibility space of off-target activity and genomic stability following genome editing. Also provided are the materials and techniques which enable the comprehensive genomic stability accompanying a range of cellular perturbations, including genome editing (ZFN, TALEN, CRISPR, and future technologies) and disease modeling among other applications.

Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing

Growing community of inventors

Cambridge, MA, United States of America

Aaron Smargon